These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 37845427)

  • 21. Idarucizumab: A Review as a Reversal Agent for Dabigatran.
    Syed YY
    Am J Cardiovasc Drugs; 2016 Aug; 16(4):297-304. PubMed ID: 27388764
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rationale and design of a phase III safety trial of idarucizumab in children receiving dabigatran etexilate for venous thromboembolism.
    Albisetti M; Schlosser A; Brueckmann M; Gropper S; Glund S; Tartakovsky I; Brandão LR; Reilly PA
    Res Pract Thromb Haemost; 2018 Jan; 2(1):69-76. PubMed ID: 30046708
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Global Use of Idarucizumab in Clinical Practice: Outcomes of the RE-VECTO Surveillance Program.
    Fanikos J; Murwin D; Gruenenfelder F; Tartakovsky I; França LR; Reilly PA; Kermer P; Wowern FV; Lane DA; Butcher K
    Thromb Haemost; 2020 Jan; 120(1):27-35. PubMed ID: 31470445
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Successful intravenous thrombolysis for ischemic stroke after reversal of dabigatran anticoagulation with idarucizumab: a case report.
    Agosti S; Casalino L; Rocci E; Zaccone G; Rota E
    J Med Case Rep; 2017 Aug; 11(1):224. PubMed ID: 28806993
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Idarucizumab, a specific reversal agent for dabigatran: mode of action, pharmacokinetics and pharmacodynamics, and safety and efficacy in phase 1 subjects.
    Reilly PA; van Ryn J; Grottke O; Glund S; Stangier J
    Am J Emerg Med; 2016 Nov; 34(11S):26-32. PubMed ID: 27707528
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lessons learnt from local real-life experience with idarucizumab for the reversal of dabigatran.
    Brennan Y; Favaloro EJ; Pasalic L; Keenan H; Curnow J
    Intern Med J; 2019 Jan; 49(1):59-65. PubMed ID: 29869387
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reversal of Dabigatran with Idarucizumab.
    Sodha NR; Sellke FW
    Expert Rev Cardiovasc Ther; 2016 Aug; 14(8):889-93. PubMed ID: 27362456
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of Idarucizumab to Revert the Anticoagulant Effect of Dabigatran in Heart Transplant Surgery: An Institutional Experience.
    Herrera-Escandón Á; Castaño-Cifuentes O; Plata-Mosquera CA
    Case Rep Cardiol; 2020; 2020():6927423. PubMed ID: 32206355
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Successful thrombolytic therapy with recombinant tissue plasminogen activator in ischemic stroke after idarucizumab administration for reversal of dabigatran: a case report.
    Ohtani T; Sintoku R; Yajima T; Kaneko N
    J Med Case Rep; 2019 Dec; 13(1):390. PubMed ID: 31875786
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characteristics of Japanese Patients with Nonvalvular Atrial Fibrillation on Anticoagulant Treatment: A Descriptive Analysis of J-dabigatran Surveillance and JAPAF Study.
    Koretsune Y; Kusakawa K; Harada KH; Koizumi A; Uchiyama S; Atarashi H; Okumura K; Yasaka M; Yamashita T; Taniguchi A; Fukaya T; Inoue H;
    Cardiol Ther; 2019 Jun; 8(1):43-54. PubMed ID: 30746608
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Effectiveness and safety of idarucizumab in the management of perioperative complications of atrial fibrillation catheter ablation in atrial fibrillation patients under dabigatran therapy].
    Li SN; Zhang JR; Li CY; Dai WL; Jia CQ; Li X; Ning M; Du X; Dong JZ; Ma CS
    Zhonghua Xin Xue Guan Bing Za Zhi; 2021 Mar; 49(3):217-223. PubMed ID: 33706454
    [No Abstract]   [Full Text] [Related]  

  • 32. Idarucizumab, a Humanized, Monoclonal Antibody Fragment for Immediate Reversal of Dabigatran.
    Miyares MA; Kuyumjian Y; Eaves S; Dollard E
    J Pharm Pract; 2015 Dec; 28(6):548-54. PubMed ID: 26894245
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intravenous Thrombolysis After Reversal of Dabigatran With Idarucizumab in Acute Ischemic Stroke: A Case Report.
    Xie D; Wang X; Li Y; Chen R; Zhao Y; Xu C; Zhang Q; Zhang Y
    Front Aging Neurosci; 2021; 13():765037. PubMed ID: 34970137
    [No Abstract]   [Full Text] [Related]  

  • 34. Drug Utilization Pattern of Oral Anticoagulants in Patients with Atrial Fibrillation: A Nationwide Population-Based Study in Korea.
    Lee MY; Han S; Bang OY; On YK; Jang SW; Han S; Ryu J; Park YJ; Kang S; Suh HS; Kim YH
    Adv Ther; 2022 Jul; 39(7):3112-3130. PubMed ID: 35524839
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study.
    Glund S; Stangier J; van Ryn J; Schmohl M; Moschetti V; Haazen W; De Smet M; Gansser D; Norris S; Lang B; Reilly P; Kreuzer J
    Clin Pharmacokinet; 2017 Jan; 56(1):41-54. PubMed ID: 27317414
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Healthcare resource utilization in patients receiving idarucizumab for reversal of dabigatran anticoagulation due to major bleeding, urgent surgery, or procedural interventions: interim results from the RE-VERSE AD™ study.
    Pollack CV; Bernstein R; Dubiel R; Reilly P; Gruenenfelder F; Huisman MV; Kam CW; Kleine E; Levy JH; Sellke FW; Steiner T; Ustyugova A; Weitz JI
    J Med Econ; 2017 May; 20(5):435-442. PubMed ID: 27981865
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics of idarucizumab and its target dabigatran in patients requiring urgent reversal of the anticoagulant effect of dabigatran.
    Glund S; Coble K; Gansser D; Stangier J; Hoermann K; Pollack CV; Reilly P
    J Thromb Haemost; 2019 Aug; 17(8):1319-1328. PubMed ID: 31050868
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessment of patients post reversal with idarucizumab.
    Raco V; Ahuja T; Green D
    J Thromb Thrombolysis; 2018 Nov; 46(4):466-472. PubMed ID: 30120649
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The first use of iv. idarucizumab for dabigatran reversal in Hungary].
    Driesz L; Barabás É; Bodócs I; Szántó Z; Herr G; Bencsik G; Pál L; Borbola J
    Orv Hetil; 2017 Mar; 158(10):387-392. PubMed ID: 28270004
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of Idarucizumab to reverse the anticoagulant effect of dabigatran in cardiac transplant surgery. A multicentric experience in Spain.
    Crespo-Leiro MG; López-Vilella R; López Granados A; Mirabet-Pérez S; Díez-López C; Barge-Caballero E; Segovia-Cubero J; González-Vilchez F; Rangel-Sousa D; Blasco-Peiró T; de la Fuente-Galán L; Díaz-Molina B; Zatarain-Nicolás E; Carrasco Ávalos F; Almenar-Bonet L
    Clin Transplant; 2019 Dec; 33(12):e13748. PubMed ID: 31670852
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.